Common questions about Progendo (FAQ)
Q: What is the difference between Progendo and other progestin medications?
A: Progendo contains Progesterone Micronized, a formulation that is chemically identical to the hormone naturally produced by the human body; this is known as bioidentical progesterone. Regulatory information notes that the micronized form is specifically prepared to enhance systemic absorption when the medication is taken by mouth, making oral administration a viable method for systemic delivery.
Q: Is there a generic version of Progendo available?
A: Yes, the active ingredient in Progendo, which is progesterone micronized, is available under the brand name Progendo and as authorized generic versions. These generic options are known simply as Progesterone Capsules.
Q: Is it normal to experience nausea or dizziness after taking Progendo?
A: According to official product information, both nausea and dizziness are listed as commonly reported adverse reactions in clinical data. Dizziness may be more noticeable in the hours immediately following administration of the medication.
Q: Why does Progendo sometimes lead to feelings of confusion or lightheadedness?
A: Official documents list lightheadedness, dizziness, and confusion as possible side effects related to the central nervous system. In some reported cases, these effects may be pronounced. Due to these possibilities, activities that require high concentration should be avoided if such neurological symptoms occur.
Q: Does Progendo cause changes in mood or lead to feelings of depression or anxiety?
A: Official documents describe emotional lability, depression, nervousness, and worry as commonly reported events in clinical trials. Worsening depression in patients with a history of the condition is listed as a serious, clinically significant adverse reaction, and careful monitoring is generally advised for individuals with a history of this condition.
Q: Is it common to have breast tenderness or pain while taking Progendo?
A: Yes, breast pain and breast tenderness are listed among the commonly reported side effects in official safety documents. This is a recognized effect due to the hormonal action of the medication.
Q: Does Progendo cause unusual vaginal discharge or spotting?
A: Vaginal discharge, spotting, and breakthrough bleeding are listed among the common adverse reactions reported in clinical data. Regulatory guidance recommends that unusual or unexpected bleeding be reported.
Q: Can Progendo cause skin changes like acne or increased facial hair?
A: Official documents list skin changes, including acne, as an undesirable effect. Furthermore, changes in hair growth, such as hair loss or gain of body or facial hair, have also been reported in regulatory documents.
Q: Is it possible for Progendo to cause fluid retention or weight gain?
A: Progestin medications are generally known to potentially cause some degree of fluid retention. Additionally, regulatory documents list a change in weight, including both increase and decrease, as an adverse effect reported in clinical settings.
Q: Does Progendo affect blood sugar levels or is it a concern for people with diabetes?
A: Official safety information notes that a decrease in glucose tolerance has been observed in a small percentage of patients using hormone therapy combinations. Because of this, diabetic patients may require careful monitoring during therapy.
Q: Can Progendo affect the results of other blood tests?
A: Official documents note that this medication may interfere with the results of certain laboratory tests, potentially causing false test results. Regulatory information suggests informing lab personnel and healthcare providers that you are taking this drug.
Q: What are the serious, but rare, side effects that require immediate medical attention?
A: Serious, clinically significant risks listed in official documents include signs of blood clots (such as DVT, PE, stroke, or MI), sudden partial or complete vision loss, symptoms of liver disease (like jaundice), and signs of Toxic Shock Syndrome (TSS). Immediate medical evaluation is warranted if any of these signs are suspected.
Q: Are there any specific safety rules regarding driving or operating machinery while on Progendo?
A: Regulatory documents advise that activities requiring concentration, coordination, or reflex action, such as driving or operating machinery, should be avoided if neurological symptoms like drowsiness or dizziness occur after taking the medicine.
Q: Does Progendo have any known interactions with alcohol?
A: Regulatory information indicates that alcohol abuse may increase the systemic bioavailability of the drug, which means more progesterone enters the bloodstream. Furthermore, alcohol consumption may worsen side effects such as dizziness or drowsiness, and official guidance recommends limiting its consumption.
Q: Can Progendo interact with grapefruit juice?
A: Grapefruit juice is noted in regulatory information as a substance that may increase the blood levels of progesterone. This is due to its effect on certain liver enzymes involved in drug metabolism.
Q: Can Progendo interact with common herbal supplements like St. John's Wort?
A: Regulatory information indicates that co-administration with potent liver enzyme inducers may increase the metabolism of progesterone. St. John's Wort is commonly listed as an herbal product that may interact via this enzyme mechanism, potentially leading to altered systemic exposure of the drug.
Q: Are there any known severe interactions between Progendo and antibiotics?
A: Regulatory information indicates that certain antibiotics, such as ampicillin and tetracyclines, may interact with progesterone. This interaction occurs by modifying the intestinal flora, which can lead to a change in the circulation of the hormone.
Q: What does the research say about Progendo's use in combination with estrogen therapy?
A: Official indications and related research confirm the drug is used with estrogen therapy to reduce the risk of changes to the uterus lining. Studies on this combined hormone therapy have also examined themes related to bone mineral density and fracture risk reduction in the studied populations.
Q: How long do the effects of Progendo last after a single administration?
A: Pharmacokinetic studies show that blood levels of progesterone begin to rise within the first hour after oral administration. Concentrations typically reach their peak, or highest level, between one and three hours post-dose.
Q: Is Progendo used to prevent a miscarriage or preterm birth?
A: The approved indications for this oral formulation do not include the prevention of miscarriage or preterm birth. Regulatory documents note that the FDA has approved a distinct progesterone formulation for addressing the risk of recurrent preterm birth.
Q: Why is Progendo sometimes prescribed for women who have had a premature delivery before?
A: The approved indications for this oral formulation do not include the prevention of miscarriage or preterm birth. Regulatory documents note that the FDA has approved a distinct progesterone formulation for addressing the risk of recurrent preterm birth.
Q: What is the official information regarding Progendo and potential birth defects?
A: The oral formulation is typically not recommended for use during pregnancy. While the medication has been studied for luteal phase support in some clinical trials, official information advises that the potential risks and benefits of use should be evaluated by a healthcare provider.
Q: Can men use Progendo for any approved medical conditions?
A: The medication is indicated and approved for use in adult women for specific conditions, such as reducing the risk of endometrial hyperplasia when used with estrogen therapy. Its use in men is not included in the official indications.
Q: Is Progendo approved for use in adolescents or only in adults?
A: Regulatory information indicates the medication is approved for use in adult women. Its use is not established, indicated, or recommended in the pediatric population, which includes adolescents.
Q: Does Progendo affect bone density or increase the risk of osteoporosis?
A: Research concerning the use of this drug in combination with estrogen replacement therapy has shown a beneficial association with reducing total fractures and increasing bone mineral density in the studied populations.
